Swedish investment company Fidelio Capital has bought the European veterinary business of research-based biopharmaceutical company ALK and all associated veterinary products (Artuvetrin) for an undisclosed sum.
The deal, effective from 1 January, will see ALK – a worldwide market leader in allergen-specific immunotherapy – continue to operate under the name ArtuVet Animal Health BV.
Founded in 1923, the company is best known for manufacturing the only licensed intradermal allergy test and allergen specific immunotherapy for dogs in Europe (licensed in the Netherlands).
Business as usual
Other than the change of name and ownership, the company says little else will change.
An official statement to the veterinary profession read: “The production of all Artuvetrin products (Artuvetrin Therapy, Artuvetrin Serum Test and Artuvetrin Skin Test) will be continued in Lelystad, the Netherlands. All contact persons and details will not change. Please be assured Artuvet will continue to supply the Artuvetrin products and offer you and your clients the utmost quality and service.
“We are looking forward to a successful future together with you and we will continue to give the best support to your atopic patients.”
- For further details and contact information, visit artuvetrin.com